Parameter | 120 μg | 240 μg | Placebo |
---|---|---|---|
Number of patients evaluated | 36 | 41 | 35 |
Number of patients who experienced ADR | 7 (19.4Â %) | 13 (31.7Â %) | 5 (14.3Â %) |
Number of patients who experienced serious ADR | 2 (5.6Â %) | 0 (0.0Â %) | 0 (0.0Â %) |
Number of patients who discontinued the study treatment due to ADR | 3 (8.3Â %) | 5 (12.2Â %) | 0 (0.0Â %) |
Number of patients who interrupted the study treatment due to ADR | 0 (0.0Â %) | 1 (2.4Â %) | 0 (0.0Â %) |